APO RESEARCH · REPORT
Bio Pharma Buffer
A buffer solution is comprised of a weak conjugate acid-base pair, for example, a weak acid and its conjugate base, or a weak base and its conjugate acid. Small quantities of other acids or bases are neutralized when added to the solution, and as a result, the solution resists changes in pH. Solutions with stable pH are required for the processing of protein-based biologic APIs because of their sensitivity to changes in pH. The stable pH range and capacity (the amount of acid/base that can be added without a change in pH) of a buffer are determined by the conjugate acid-base pair.
Product & engineering
Understand the product.
A buffer solution is comprised of a weak conjugate acid-base pair, for example, a weak acid and its conjugate base, or a weak base and its conjugate acid. Small quantities of other acids or bases are neutralized when added to the solution, and as a result, the solution resists changes in pH. Solutions with stable pH are required for the processing of protein-based biologic APIs because of their sensitivity to changes in pH. The stable pH range and capacity (the amount of acid/base that can be added without a change in pH) of a buffer are determined by the conjugate acid-base pair.
Most purification steps for downstream processing of biologics require buffers to equilibrate, condition, wash, elute, or concentrate the product. They are used in product isolation and purification steps to facilitate protein capture and polishing and also in the filtration process for the removal of viruses or depyrogenation. Aqueous solutions are also required for cleaning and disinfecting downstream processing equipment, such as chromatography matrices and membrane filtration systems. The main equipment involved in downstream processing with buffers includes mixers for buffer preparation, as well as equipment for purification, including packed-bed chromatography systems, fluidized beds, ultrafiltration and diafiltration membranes, microfiltration membranes, depth filtration cartridges, and virus-removal systems.
Selected research
Market Structure
Global Bio Pharma Buffer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
A buffer solution is comprised of a weak conjugate acid-base pair, for example, a weak acid and its conjugate base, or a weak base and its conjugate acid. Small quantities of other acids or bases are neutralized when added to the solution, and as a result, the solution resists changes in pH. Solutions with stable pH are required for the processing of protein-based biologic APIs because of their sensitivity to changes in pH. The stable pH range and capacity (the amount of acid/base that can be added without a change in pH) of a buffer are determined by the conjugate acid-base pair.
Most purification steps for downstream processing of biologics require buffers to equilibrate, condition, wash, elute, or concentrate the product. They are used in product isolation and purification steps to facilitate protein capture and polishing and also in the filtration process for the removal of viruses or depyrogenation. Aqueous solutions are also required for cleaning and disinfecting downstream processing equipment, such as chromatography matrices and membrane filtration systems. The main equipment involved in downstream processing with buffers includes mixers for buffer preparation, as well as equipment for purification, including packed-bed chromatography systems, fluidized beds, ultrafiltration and diafiltration membranes, microfiltration membranes, depth filtration cartridges, and virus-removal systems.
The key players are Avantor, Alfa Aesar (Thermo Fisher), Merck, Lonza, Bio-Rad, BD, GE, Healthcare, Promega Corporation, Hamilton Company, XZL BIO-TECHNOLOGY, SRL and so on. According to the revenue of these companies, we can know that the Bio Pharma Buffer industry is relative concentrated. Because the top 6 companies have more than 70% market share.
Read the full market overview
This report provides an overview of the global Bio Pharma Buffer market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Bio Pharma Buffer and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Bio Pharma Buffer sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Bio Pharma Buffer market size, projected growth trends, production technologies, key applications, and end-use industries.
Bio Pharma Buffer Segment by Company
Avantor
Alfa Aesar (Thermo Fisher)
Merck
Lonza
Bio-Rad
BD
GE Healthcare
Promega Corporation
Hamilton Company
XZL BIO-TECHNOLOGY
SRL
Bio Pharma Buffer Segment by Type
Phosphates Type
Acetates Type
TRIS Type
Others
Bio Pharma Buffer Segment by Application
Research Institution
Pharmaceutical Industry
Others
Bio Pharma Buffer Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bio Pharma Buffer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Bio Pharma Buffer and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bio Pharma Buffer.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Bio Pharma Buffer market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Bio Pharma Buffer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Bio Pharma Buffer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Bio Pharma Buffer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Phosphates Type
- Acetates Type
- TRIS Type
- Others
Applications
- Research Institution
- Pharmaceutical Industry
- Others
Companies covered
- Avantor
- Alfa Aesar (Thermo Fisher)
- Merck
- Lonza
- Bio-Rad
- BD
- GE Healthcare
- Promega Corporation
- Hamilton Company
- XZL BIO-TECHNOLOGY
- SRL
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Bio Pharma Buffer Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Bio Pharma Buffer Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Bio Pharma Buffer Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Bio Pharma Buffer Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Bio Pharma Buffer Market Dynamics
- 2.1 Bio Pharma Buffer Industry Trends
- 2.2 Bio Pharma Buffer Industry Drivers
- 2.3 Bio Pharma Buffer Industry Opportunities and Challenges
- 2.4 Bio Pharma Buffer Industry Restraints
3 Bio Pharma Buffer Market by Manufacturers
- 3.1 Global Bio Pharma Buffer Revenue by Manufacturers (2021-2026)
- 3.2 Global Bio Pharma Buffer Sales by Manufacturers (2021-2026)
- 3.3 Global Bio Pharma Buffer Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Bio Pharma Buffer Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Bio Pharma Buffer Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Bio Pharma Buffer Manufacturers, Product Type & Application
- 3.7 Global Bio Pharma Buffer Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Bio Pharma Buffer Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Bio Pharma Buffer Players Market Share by Revenue in 2025
- 3.8.3 2025 Bio Pharma Buffer Tier 1, Tier 2, and Tier 3
4 Bio Pharma Buffer Market by Type
- 4.1 Bio Pharma Buffer Type Introduction
- 4.1.1 Phosphates Type
- 4.1.2 Acetates Type
- 4.1.3 TRIS Type
- 4.1.4 Others
- 4.2 Global Bio Pharma Buffer Sales by Type
- 4.2.1 Global Bio Pharma Buffer Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Bio Pharma Buffer Sales by Type (2021-2032)
- 4.2.3 Global Bio Pharma Buffer Sales Market Share by Type (2021-2032)
- 4.3 Global Bio Pharma Buffer Revenue by Type
- 4.3.1 Global Bio Pharma Buffer Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Bio Pharma Buffer Revenue by Type (2021-2032)
- 4.3.3 Global Bio Pharma Buffer Revenue Market Share by Type (2021-2032)
5 Bio Pharma Buffer Market by Application
- 5.1 Bio Pharma Buffer Application Introduction
- 5.1.1 Research Institution
- 5.1.2 Pharmaceutical Industry
- 5.1.3 Others
- 5.2 Global Bio Pharma Buffer Sales by Application
- 5.2.1 Global Bio Pharma Buffer Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Bio Pharma Buffer Sales by Application (2021-2032)
- 5.2.3 Global Bio Pharma Buffer Sales Market Share by Application (2021-2032)
- 5.3 Global Bio Pharma Buffer Revenue by Application
- 5.3.1 Global Bio Pharma Buffer Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Bio Pharma Buffer Revenue by Application (2021-2032)
- 5.3.3 Global Bio Pharma Buffer Revenue Market Share by Application (2021-2032)
6 Global Bio Pharma Buffer Sales by Region
- 6.1 Global Bio Pharma Buffer Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Bio Pharma Buffer Sales by Region (2021-2032)
- 6.2.1 Global Bio Pharma Buffer Sales by Region (2021-2026)
- 6.2.2 Global Bio Pharma Buffer Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Bio Pharma Buffer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Bio Pharma Buffer Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Bio Pharma Buffer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Bio Pharma Buffer Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Bio Pharma Buffer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Bio Pharma Buffer Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Bio Pharma Buffer Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Bio Pharma Buffer Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Bio Pharma Buffer Revenue by Region
- 7.1 Global Bio Pharma Buffer Revenue by Region
- 7.1.1 Global Bio Pharma Buffer Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Bio Pharma Buffer Revenue by Region (2021-2026)
- 7.1.3 Global Bio Pharma Buffer Revenue by Region (2027-2032)
- 7.1.4 Global Bio Pharma Buffer Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Bio Pharma Buffer Revenue (2021-2032)
- 7.2.2 North America Bio Pharma Buffer Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Bio Pharma Buffer Revenue (2021-2032)
- 7.3.2 Europe Bio Pharma Buffer Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Bio Pharma Buffer Revenue (2021-2032)
- 7.4.2 Asia-Pacific Bio Pharma Buffer Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Bio Pharma Buffer Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Bio Pharma Buffer Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Avantor
- 8.1.1 Avantor Company Information
- 8.1.2 Avantor Business Overview
- 8.1.3 Avantor Bio Pharma Buffer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Avantor Bio Pharma Buffer Product Portfolio
- 8.1.5 Avantor Recent Developments
- 8.2 Alfa Aesar (Thermo Fisher)
- 8.2.1 Alfa Aesar (Thermo Fisher) Company Information
- 8.2.2 Alfa Aesar (Thermo Fisher) Business Overview
- 8.2.3 Alfa Aesar (Thermo Fisher) Bio Pharma Buffer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Alfa Aesar (Thermo Fisher) Bio Pharma Buffer Product Portfolio
- 8.2.5 Alfa Aesar (Thermo Fisher) Recent Developments
- 8.3 Merck
- 8.3.1 Merck Company Information
- 8.3.2 Merck Business Overview
- 8.3.3 Merck Bio Pharma Buffer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Merck Bio Pharma Buffer Product Portfolio
- 8.3.5 Merck Recent Developments
- 8.4 Lonza
- 8.4.1 Lonza Company Information
- 8.4.2 Lonza Business Overview
- 8.4.3 Lonza Bio Pharma Buffer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Lonza Bio Pharma Buffer Product Portfolio
- 8.4.5 Lonza Recent Developments
- 8.5 Bio-Rad
- 8.5.1 Bio-Rad Company Information
- 8.5.2 Bio-Rad Business Overview
- 8.5.3 Bio-Rad Bio Pharma Buffer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Bio-Rad Bio Pharma Buffer Product Portfolio
- 8.5.5 Bio-Rad Recent Developments
- 8.6 BD
- 8.6.1 BD Company Information
- 8.6.2 BD Business Overview
- 8.6.3 BD Bio Pharma Buffer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 BD Bio Pharma Buffer Product Portfolio
- 8.6.5 BD Recent Developments
- 8.7 GE Healthcare
- 8.7.1 GE Healthcare Company Information
- 8.7.2 GE Healthcare Business Overview
- 8.7.3 GE Healthcare Bio Pharma Buffer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 GE Healthcare Bio Pharma Buffer Product Portfolio
- 8.7.5 GE Healthcare Recent Developments
- 8.8 Promega Corporation
- 8.8.1 Promega Corporation Company Information
- 8.8.2 Promega Corporation Business Overview
- 8.8.3 Promega Corporation Bio Pharma Buffer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Promega Corporation Bio Pharma Buffer Product Portfolio
- 8.8.5 Promega Corporation Recent Developments
- 8.9 Hamilton Company
- 8.9.1 Hamilton Company Company Information
- 8.9.2 Hamilton Company Business Overview
- 8.9.3 Hamilton Company Bio Pharma Buffer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Hamilton Company Bio Pharma Buffer Product Portfolio
- 8.9.5 Hamilton Company Recent Developments
- 8.10 XZL BIO-TECHNOLOGY
- 8.10.1 XZL BIO-TECHNOLOGY Company Information
- 8.10.2 XZL BIO-TECHNOLOGY Business Overview
- 8.10.3 XZL BIO-TECHNOLOGY Bio Pharma Buffer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 XZL BIO-TECHNOLOGY Bio Pharma Buffer Product Portfolio
- 8.10.5 XZL BIO-TECHNOLOGY Recent Developments
- 8.11 SRL
- 8.11.1 SRL Company Information
- 8.11.2 SRL Business Overview
- 8.11.3 SRL Bio Pharma Buffer Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 SRL Bio Pharma Buffer Product Portfolio
- 8.11.5 SRL Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Bio Pharma Buffer Value Chain Analysis
- 9.1.1 Bio Pharma Buffer Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Bio Pharma Buffer Production Mode & Process
- 9.2 Bio Pharma Buffer Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Bio Pharma Buffer Distributors
- 9.2.3 Bio Pharma Buffer Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst